Thursday August 21st
 
 
 


UNITED STATES - 226 news CANADA - 44 news UNITED KINGDOM - 31 news GERMANY - 30 news AUSTRALIA - 29 news SWITZERLAND - 14 news SWEDEN - 14 news FRANCE - 11 news DENMARK - 8 news NORWAY - 8 news NETHERLANDS - 6 news ISRAEL - 5 news JAPAN - 5 news ITALY - 4 news BELGIUM - 3 news IRELAND - 3 news AUSTRIA - 2 news SPAIN - 2 news FINLAND - 2 news INDIA - 2 news ICELAND - 2 news PORTUGAL - 1 news Most active countries (last 30 days) [enlarge]

 

  Next
[ 45 ]
[ 42 ]
[ 36 ]
[ 27 ]
[ 25 ]
[ 23 ]
[ 21 ]
[ 20 ]
[ 20 ]
[ 20 ]
[ 19 ]
[ 18 ]
[ 18 ]
[ 16 ]
[ 16 ]
[ 14 ]
[ 14 ]
[ 14 ]
[ 13 ]
[ 12 ]
Most active sources (last 90 days)
 
-
-
[Interview]
 

::: Acorda Therapeutics' Preclinical Pipeline Named One of the 10 Most Promising Neuroscience Projects Available for Partnering by Windhover
Acorda Therapeutics, Acorda plans, Preclinical Pipeline, Director of Windhover Information, selected company, attractive neuroscience opportunities, Promising Neuroscience Projects Available, multi-level partnering opportunities, interesting neuroscience projects, independent neuroscience expert
::: Revolutions Medical Finishes Filing Its International Patent Protection for the Rev Vac Safety Syringe
control of Revolutions Medical Corporation, Revolutions Medical Finishes Filing, proprietary Rev Vac safety syringe, medical industry, proprietary Rev Color MRI, safety-engineered medical devices, Rev 3D MRI technology, filing additional international patent protection, Europe international patent protection rights, Rev Med MRI technologies
::: Javelin Presents Successful Pivotal Phase 3 Secondary Clinical Results for Dyloject™ at the 12th World Congress on Pain
Dyloject demonstrating, Dyloject given IV, Dyloject groups, Dyloject 18.75 mg, Dyloject offers safe, Javelin Pharmaceuticals, World Congress, pivotal Phase 3 study of Dyloject, pain relief, pain management
::: PolyMedix Initiates Dosing in Phase I Clinical Study of Novel Systemic Antibiotic Compound
successful completion of the first clinical study, second clinical trial, Clinical Trial Application, major clinical, Human Clinical Trials, clinical dosing regimen, clinical development, defensin mimetic antibiotic compound, Defensin Mimetic Systemic Antibiotic Drug
::: International Stem Cell Corporation Arranges $ 3 Million Equity Financing
Cell Corporation, Forward-Looking Statements, subsidiary Lifeline Cell Technology, cell lines, construction of therapeutic cell, ISCO website, ISCO scientists, Cell Bank, Statements pertaining, therapeutic research

search powered by PERTIMM: 'the discover engine'